PALVELLA THERAPEUTICS, INC. Form 8-K Summary

Filing Date: November 5, 2025

Key Event (Item 8.01):

• Announcement of a new product candidate: QTORIN™ pitavastatin.
• Indication: Treatment of disseminated superficial actinic porokeratosis (DSAP).

Investor Communications (Item 7.01):

• The Company is hosting an investor conference call on November 5, 2025, at 8:30 a.m. ET to present the new candidate.
• Investor presentation materials (Exhibit 99.1) and the official press release (Exhibit 99.2) are furnished.

Investor Relevance: This filing formally a